Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 487

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Open access
Orkin, Chloe, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Overton, Edgar T., Girard, Pierre-Marie, Oka, Shinichi, Walmsley, Sharon, Bettacchi, Chris, Brinson, Cynthia, Philibert, Patrick, Lombaard, Johan, St. Clair, Marty, Crauwels, Herta, Ford, Susan L., Patel, Parul, Chounta, Vasiliki, D’Amico, Ronald, Vanveggel, Simon, Dorey, David, Cutrell, Amy, Griffith, Sandy, Margolis, David A., Williams, Peter E., Parys, Wim, Smith, Kimberly Y., Spreen, William R. · 2020 · New England Journal of Medicine

Abstract

BACKGROUND: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine. The primary end point was the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (Food and Drug Administration snapshot algorithm). RESULTS: At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received oral therapy (adjusted difference, -0.4 percentage points; 95% confidence interval [CI], -2.8 to 2.1), a result that met the criterion for noninferiority for the primary end point (margin, 6 percentage points). An HIV-1 RNA level of less than 50 copies per milliliter at week 48 was found in 93.6% who received long-acting therapy and in 93.3% who received oral therapy (adjusted difference, 0.4 percentage points; 95% CI, -3.7 to 4.5), a result that met the criterion for noninferiority for this end point (margin, -10 percentage points). Of the participants who received long-acting therapy, 86% reported injection-site reactions (median duration, 3 days; mild or moderate severity, 99% of cases); 4 participants withdrew from the trial for injection-related reasons. Grade 3 or higher adverse events and events that met liver-related stopping criteria occurred in 11% and 2%, respectively, who received long-acting therapy and in 4% and 1% who received oral therapy. Treatment satisfaction increased after participants switched to long-acting therapy; 91% preferred long-acting therapy at week 48. CONCLUSIONS: Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravir-abacavir-lamivudine with regard to maintaining HIV-1 suppression. Injection-site reactions were common. (Funded by ViiV Healthcare and Janssen; FLAIR ClinicalTrials.gov number, NCT02938520.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1909512

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 487

Metadata

Authors
Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P.-M., Oka, S., Walmsley, S., Bettacchi, C., Brinson, C., Philibert, P., Lombaard, J., St. Clair, M., Crauwels, H., Ford, S. L., Patel, P., Chounta, V., D’Amico, R., Vanveggel, S., Dorey, D., Cutrell, A., Griffith, S., Margolis, D. A., Williams, P. E., Parys, W., Smith, K. Y., & Spreen, W. R.
Venue
New England Journal of Medicine
Published
2020-03-19
Volume
382
Issue
12
Pages
1124-1135
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3010513804
Cited by
487
References
16
FWCI
7.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.